Aktuellt
SENASTE
Redeye maintains a positive view on LIDDS after today's Q2 report. The company is building value in its portfolio and is supported by a strong global trend that will bring cancer treatment to the top of the healthcare priority list in the coming years, in our view.
LÄS MER
